Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Real-world Aliskiren Use in Diabetic Patients
- Conditions
- DiabetesHypertension
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT01393860
- Locations
- 🇺🇸
MODEL Clinical Research, Research Division of Bay Endocrinology Associates GBMC Physicians pavilion North, Baltimore, Maryland, United States
Efficacy and Safety of Diclofenac 1.16% Gel in Subjects With Acute Neck Pain
- Conditions
- Neck Pain
- Interventions
- Drug: Placebo gel
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2012-07-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 72
- Registration Number
- NCT01335724
- Locations
- 🇩🇪
NCH investigative site, Munich, Germany
Drug Use Investigation for TYKERB Tablet (All Case Investigation)
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 4054
- Registration Number
- NCT01332396
Efficacy of DNK333 in Patients With COPD and Cough
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: PlaceboDrug: DNK333 100 mg twice daily
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 28
- Registration Number
- NCT01287325
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 64
- Registration Number
- NCT01281657
- Locations
- 🇺🇸
North Central Neurology Associates, PC, Cullman, Alabama, United States
🇺🇸The Research & Education Inst. of Alta Bates Summit Med. Grp, Berkeley, California, United States
🇺🇸Neuro-Therapeutics, Inc., Pasadena, California, United States
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Ankle Sprain
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 205
- Registration Number
- NCT01272934
- Locations
- 🇩🇪
NCH investigative site, Gilching, Germany
🇩🇪NCH investigative site, Munich, Germany., Munich, Germany
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma Injuries
- Conditions
- Acute Blunt Soft Tissue Injuries/Contusions
- Interventions
- Other: Placebo
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 204
- Registration Number
- NCT01272947
- Locations
- 🇩🇪
NCH investigative site, Munich, Germany
Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.
- Conditions
- Sore Throat Due to a Common Cold
- Interventions
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 250
- Registration Number
- NCT01265446
- Locations
- 🇩🇪
Socratec, Erfurt, Germany
A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 14075
- Registration Number
- NCT01256658
- Locations
- 🇧🇫
Novartis Investigative Site, Burkina Faso, Burkina Faso
🇧🇫Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
🇧🇫Novartis Investigative site, Ouagadougou, Burkina Faso
Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients
- Conditions
- Renal Transplant
- Interventions
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2012-06-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 71
- Registration Number
- NCT01256294
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States